The distribution of lipopolysaccharide in normocomplementemic and C3-depleted rabbits and rhesus monkeys. 1980

J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane

To examine the role of complement (C3) in determining the fate of lipopolysaccharide (LPS) in vivo, the distribution of LPS was studied in normocomplementemic (NC) and C3-depleted animals (pretreated with cobra venom factor [CoF]) after intravenous injection of highly purified, radioiodinated Salmonella minnesota R595 LPS. After injection of a lethal (250 micrograms) or nonlethal (5 micrograms) dose of LPS in NC and CoF rabbits and a lethal (5 mg/kg) dose of LPS in rhesus monkeys, the LPS disappeared from blood in a biphasic manner. In all cases, a substantial portion of the dose was removed from blood in an initial disappearance phase (t1/2 < 15 minutes), which, in some cases, was accelerated in CoF-treated animals. LPS remaining in blood beyond 30 minutes persisted with a much increased half-life (> 5 hours). Liver contained the major portion (40%) of tissue-bound LPS (determined by use of 131I-BSA blood marker) in animals killed 3--5 hours after injection. The distribution of LPS in rabbits was found to be dose-indpendent and only minimally changed by prior depletion of C3. In addition, the tissue distribution and cellular localization of LPS in monkeys was similar to that we have reported previously for R595 LPS in NC rabbits and was not substantially changed by prior CoF treatment. These results indicate that binding of C3 to intravenously injected LPS is not required for the initial rapid disappearance from blood. Further, the uptake of LPS by cellular targets, notably the hepatic macrophages (Kupffer cells), is not altered by in vivo decomplementation.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D008297 Male Males
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D004546 Elapid Venoms Venoms from snakes of the family Elapidae, including cobras, kraits, mambas, coral, tiger, and Australian snakes. The venoms contain polypeptide toxins of various kinds, cytolytic, hemolytic, and neurotoxic factors, but fewer enzymes than viper or crotalid venoms. Many of the toxins have been characterized. Cobra Venoms,Elapidae Venom,Elapidae Venoms,Naja Venoms,Cobra Venom,Elapid Venom,Hydrophid Venom,Hydrophid Venoms,King Cobra Venom,Naja Venom,Ophiophagus hannah Venom,Sea Snake Venom,Sea Snake Venoms,Venom, Cobra,Venom, Elapid,Venom, Elapidae,Venom, Hydrophid,Venom, King Cobra,Venom, Naja,Venom, Ophiophagus hannah,Venom, Sea Snake,Venoms, Cobra,Venoms, Elapid,Venoms, Elapidae,Venoms, Hydrophid,Venoms, Naja,Venoms, Sea Snake
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012475 Salmonella A genus of gram-negative, facultatively anaerobic, rod-shaped bacteria that utilizes citrate as a sole carbon source. It is pathogenic for humans, causing enteric fevers, gastroenteritis, and bacteremia. Food poisoning is the most common clinical manifestation. Organisms within this genus are separated on the basis of antigenic characteristics, sugar fermentation patterns, and bacteriophage susceptibility.
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions

Related Publications

J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
May 1977, Infection and immunity,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
June 1980, Xenobiotica; the fate of foreign compounds in biological systems,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
January 2004, Veterinary ophthalmology,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
January 1978, Neuropsychologia,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
September 1971, The Journal of experimental medicine,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
September 1971, The Journal of experimental medicine,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
December 2016, Physiological research,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
January 1961, Biokhimiia (Moscow, Russia),
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
April 2005, Primates; journal of primatology,
J C Mathison, and R J Ulevitch, and J R Fletcher, and C G Cochrane
June 1975, Nihon juigaku zasshi. The Japanese journal of veterinary science,
Copied contents to your clipboard!